A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes
- 31 August 1996
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 20 (8) , 693-699
- https://doi.org/10.1016/0145-2126(96)00034-3
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studiesBritish Journal of Haematology, 1995
- Sequential administration of recombinant human granulocyte‐macrophage colony‐stimulating factor and human erythropoietin for treatment of myelodysplasia syndromesEuropean Journal of Haematology, 1995
- Clinical use of erythropoietinCurrent Opinion in Hematology, 1995
- Recombinant human granulocyte‐macrophage colony‐stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromesAmerican Journal of Hematology, 1993
- A Combination of Granulocvte Colonv-Stimulating Factor and Erythiopoietin may Synergistically Improve the Anaemia in Patients with Myelodysplastic SyndromesLeukemia & Lymphoma, 1993
- Therapeutic aspects of myelodysplastic syndromes in chronic phaseLeukemia Research, 1992
- High-Dose Recombinant Human Erythropoietin Administered Intravenously for the Treatment of Anaemia in Myelodysplastic SyndromesActa Haematologica, 1992
- Treatment of myelodysplastic syndromes with recombinant human erythropoietinEuropean Journal of Haematology, 1991
- Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factorThe International Journal of Cell Cloning, 1990
- Demonstration of burst-promoting activity of recombinant human GM-CSF on circulating erythroid progenitors using an assay involving the delayed addition of erythropoietinBlood, 1985